· Published by Health Canada · Official notice
This is duplicated text of a letter from Amgen Canada Inc.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 16, 2012
Dear Healthcare Professional:
Subject: Association of Prolia® (denosumab) with Risk of Atypical Femoral Fracture
AMGEN Canada Inc., in consultation with Health Canada, would like to inform healthcare providers of new important safety information regarding the risk of atypical femoral fractures associated with PROLIA treatment.
PROLIA (denosumab) is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture, defined as a history of osteoporotic fracture, or multiple risk factors for fracture; or patients who have failed or are intolerant to other available osteoporosis therapy.
Atypical femoral fractures are subtrochanteric or proximal diaphyseal fractures that may occur with little or no trauma and which may be bilateral. Radiographic findings include simple transverse or oblique fracture with "beaking" of the cortex with diffuse cortical thickening of the proximal femoral shaft.Footnote 1 There have been no confirmed Canadian cases of atypical femoral fractures associated with PROLIA to date. Amgen has proactively evaluated the potential for atypical femoral fractures in patients treated with PROLIA in clinical trials and the postmarketing setting.
The Warnings and Precautions section of the PROLIA Product monograph has been updated to reflect this new information on atypical femoral fractures.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious atypical femoral fracture or other serious or unexpected adverse reactions in patients receiving PROLIA should be reported to Amgen Canada Inc. or Health Canada.
Amgen Canada Inc.
6775 Financial Drive, Suite 100
Mississauga, Ontario L5N 0A4
Safety Tel: 1-866-512-6436 or Fax: 1-888-264-3655
Safety e-mail: safetycanada@amgen.com
To correct your mailing address or fax number, contact Amgen Canada Inc.
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffectTM Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
A copy of this letter is available on the Health Canada Web site. This information is also available at Amgen Canada Web Site.
Sincerely,
original signed by
Clive Ward-Able, MD
Executive Medical Director
AMGEN Canada Inc.
Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society of Bone and Mineral Research. J Bone Miner Res. 2010;25:2267-2294.